By Conjoint Associate Professor Mark Theo Bloch

Conference Presentations

Siefried KJ; Mao L; Cysique LA; Rule J; Giles ML; Smith DE; McMahon J; Read TR; Ooi C; Tee BK; Bloch M; de wit J; Carr A, 2017, 'Polypharmacy of concomitant medications in HIV-infected Australian adults is common, and associated with adverse effects', presented at The Australasian HIV&AIDS Conference, Canberra Australia, 06 November 2017 - 08 November 2017

Conference Abstracts

Munari S; Goller JL; Wilkinson AL; Coombe J; Polkinghorne V; Traeger M; Asselin J; Chow EPF; Varma R; Martin S; Bell C; Bloch M; Hocking JS; Hellard M, 2026, 'Chlamydia prescribing trends before and after 2022 guideline update: sentinel surveillance 2015–2025', in Australian and New Zealand Journal of Public Health, Elsevier, Vol. 50, pp. 100486, http://dx.doi.org/10.1016/j.anzjph.2026.100486

Martinello M; Bartlett S; Dore G; Bopage R; Finlayson R; Baker D; Bloch M; Doyle J; Shaw D; Hajkowicz K; Read P; Filep E; Lin L; Yee J; Applegate T; Hellard M; Matthews G, 2018, 'Universal access to DAA therapy paves the way for HCV control and elimination among people living with HIV in Australia', in Universal access to DAA therapy paves the way for HCV control and elimination among people living with HIV in Australia, Paris, France, presented at THE INTERNATIONAL LIVER CONGRESS 2018, Paris, France, 11 April 2018 - 15 April 2018

Martinello M; Dore GJ; Bopage RI; Finlayson R; Baker D; Bloch M; Wilcox A; Filep E; Hellard M; Matthews GV, 2017, 'FRI-194 DAA treatment scale-up in HIV/HCV co-infection: characterisinga population at risk for reinfection', in Journal of Hepatology, Elsevier, Vol. 66, pp. s495 - s496, http://dx.doi.org/10.1016/s0168-8278(17)31388-0

Preprints

Martinello M; Yee J; Bartlett SR; Read P; Baker D; Post J; Finlayson R; Bloch M; Doyle J; Shaw D; Rowling D; Doong N; Jackson E; Hellard M; Petoumenos K; Lin L; Marks P; Applegate T; Dore GJ; Matthews GV, 2018, Moving Towards HCV Elimination Among People Living with HIV in Australia: Analysis of the CEASE Prospective Cohort Study, http://dx.doi.org/10.2139/ssrn.3269607

Dharan NJ; Yeh P; Bloch M; Yeung M; Baker D; Guinto J; Roth N; Ftouni S; Ognenovska K; Smith D; Hoy JF; Woolley I; Pell C; Templeton DJ; Fraser N; Rose N; Hutchinson J; Petoumenos K; Dawson S-J; Polizzotto MN; Dawson MA; Group FTAS, Age-related clonal haematopoiesis is more prevalent in older adults with HIV: the ARCHIVE study, http://dx.doi.org/10.1101/2020.11.19.20235069

Dawson M; Dharan N; Yeh P; Bloch M; Yeung M; Baker D; Guinto J; Roth N; Ftouni S; Ognenovska K; Smith D; Hoy J; Woolley I; Pell C; Templeton D; Fraser N; Rose N; Hutchinson J; Petoumenos K; Dawson S-J; Polizzotto M, Age-related clonal haematopoiesis is more prevalent in older adults with HIV: the ARCHIVE study, http://dx.doi.org/10.21203/rs.3.rs-106576/v1

Dharan NJ; Sasson SC; Ahlenstiel G; Andersen CR; Bloch M; Buckland G; Hamad N; Han WM; Kelleher AD; Long GV; Matthews GV; Mina MM; Papot E; Petoumenos K; Swaminathan S; Withers B; Yun J; Polizzotto MN, Clinical and laboratory features of COVID-19 illness and outcomes in immunocompromised individuals during the first pandemic wave in Sydney, Australia, http://dx.doi.org/10.1101/2023.08.17.23293358

Bennett C; Rivers EJ; Woo W; Bloch M; Cheung ; Griffin P; Mohan R; Deshmukh S; Arya M; Cumming O; Neville AM; Pardey TM; Plested JS; Cloney-Clark S; Zhu M; Kalkeri R; Patel N; Buchanan A; Marcheschi A; Swan J; Smith G; Cho I; Glenn GM; Walker R; Mallory RM, Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial, http://dx.doi.org/10.1101/2023.07.05.23291954

Back to profile page